Ruxolitinib is a medication used to manage and treat myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It is in the Janus Kinase inhibitor class of medications. This activity reviews the indications, action, and contraindications for ruxolitinib as a valuable agent in managing myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of the interprofessional team in managing patients with myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease and their related conditions.

**Objectives:**
- Identify the indications for ruxolitinib therapy. 
- Identify the most common adverse events associated with ruxolitinib therapy. 
- Explain the importance of monitoring for patients on ruxolitinib, including complete blood count. 
- Summarize some interprofessional strategies that can improve therapeutic outcomes when using ruxolitinib therapy.